Rating
Buy
Price target
$195
Previous
$135
Implied upside
+11%

Wells Fargo analyst Gary Mobley raised the price target on Marvell Technology (NASDAQ: MRVL) to $195.00 (from $135.00) while maintaining an Overweight rating.

“Significant AWS Trainium Expansion Ahead.

MRVL has guided its Custom XPU rev growth at >20% y/y in FY27, but more notably guided FY28 at +2x y/y – driven by ramping AWS Trainium v2 + v3 deploys + Microsoft Maia ($700M+ in FY28).

We see investor sentiment focused on MRVL’s upside to 30-40%+ y/y growth driven by AWS’ own expansion, and more notably, incremental growth driven by OpenAI (late-Feb) & Anthropic Trainium commitments; AMZN reporting $225B in Trainium commits exiting C1Q26.

Wells’ Analyst, Ken Gawrelski, currently ests AWS’ Trainium GW capacity deploy will expand by >2GWs per annum in CY27-CY29.

If we were to simply (conservatively) assume Trainium deploys at only ~$3B/GW (vs Broadcom’s $10-$20B/GW), we would arrive at MRVL’s Trainium-only rev progressing into $5.5-$6.0B/annum+ range vs our / Street current FY27 and FY28 Custom XPU rev at $2.15B / $2.06B and $4.57B / $3.93B, respectively.

We think upside could be framed in the $5-$6B+ per GW range.”

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Share

Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.